Tiziana Life Sciences Ltd (TLSA) Return on Assets ROA from the fourth quarter of 2025 to fourth quarter of 2023 and for the year 2025, Average High and Low, Fundamental Ratios from Dec 31 2025 to Dec 31 2023 - CSIMarket
Tiziana Life Sciences Ltd's ROA from the fourth quarter of 2025 to the fourth quarter of 2023 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Tiziana Life Sciences Ltd's ROA in the fourth quarter of 2025?
Tiziana Life Sciences Ltd recorded a cumulative net loss of $-18 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -160.34%.
However, within the Healthcare sector 910 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 5123.
Tiziana Life Sciences: Innovative Breakthrough and Ongoing Financial Challenges Shape Its Future In an exciting breakthrough, Tiziana Life Sciences, a renowned biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its intranasal formulation of foralumab. This formulation, a fully human anti-CD3 monoclonal antibody, is primarily developed to treat non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The recognition from the FDA is a significant milestone for Tiziana, as it signifies the potential of their immunomodulation therapies to revolutionize the field of medicine. Tiziana s leading development candidate, intranasal foralumab, has already gained attention within the scientific community due to its unique properties and potential to provide significant relief for patients suffering from na-SPMS. By leveraging innovative delivery methods, Tiziana aims to streamline treatment administration and improve patient experiences.
Tiziana Life Sciences Ltd, a biotechnology company renowned for developing groundbreaking immunomodulation therapies, has recently submitted a grant application to the ALS Association. The Company seeks to secure funding for a clinical trial of its lead development candidate, intranasal foralumab, an innovative fully human anti-CD3 monoclonal antibody. The trial aims to explore the potential of foralumab in the treatment of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that currently lacks effective therapeutic options. The ALS Association s Hoffman ALS Clinical Trial Awards Program, led by James Berry, MD, MPH, and Suma Babu, MBBS, MS, recognized Tiziana s potential and extended an invitation to apply for their prestigious grant. This program specifically supports groundbreaking clinical trials with the goal of advancing treatment options for patients suffering from ALS.
Tiziana Life Sciences, a leading biotechnology company, has made significant strides in their research and development efforts by filing a new patent application for a novel combination therapy. The proposed therapy combines anti-CD3 antibody (Foralumab) with a GLP-1 receptor agonist to target obesity-associated inflammation. This latest development comes at a crucial time for Tiziana Life Sciences, as the company recorded a notable net loss in their recent financial report. Despite these challenges, the company remains committed to finding innovative solutions within the healthcare sector. Combating Obesity-Associated Inflammation: Obesity has become a pressing concern around the world, with escalating rates of related health conditions. One such concern is obesity-associated inflammation, a condition characterized by chronic low-grade inflammation throughout the body. Tiziana Life Sciences aims to tackle this issue head-on by combining their well-known anti-CD3 antibody, Foralumab, with a GLP-1 receptor agonist.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
